doi 10.34172/aim.2022.84

Original Article

http://www.aimjournal.ir MEDICINE



ARCHIVES OF

IRANIAN

Outcome of Percutaneous Coronary Intervention in Old Patients Presenting with Acute Coronary Syndrome

Aida Fallahzadeh, MD^{1,2}; Ali Sheikhy, MD^{1,2}; Afsaneh Aein, MD³; Mojtaba Salarifar, MD⁴; Hamidreza Pourhosseini, MD⁴; Hassan Aghajani, MD⁴; Mohammad Alidoosti, MD⁴; Saeed Sadeghian, MD⁴; Kaveh Hosseini, MD^{4*}

¹Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

²Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

³Department of Health Education and Health Promotion, School of Public Health, Iran University of Medical Sciences, Tehran, Iran ⁴Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Octogenarians (age \geq 80 years) with coronary artery disease constitute a high-risk group and the elderly undergoing percutaneous coronary intervention (PCI) are at higher risk of adverse outcomes compared to young patients. In this study, we aimed to describe the outcomes of the elderly with acute coronary syndrome (ACS) who underwent PCI and also to identify the predictors of short-term major adverse cerebrocardiovascular events (MACCE) in octogenarians.

Methods: In this registry-based cohort study, we reviewed the data of patients (aged≥65 years) who underwent PCI. Univariate Cox-regression model was used to assess the univariate effects of covariates on mortality and MACCE and multivariate Cox-regression analysis were used to discover MACCE predictors.

Results: We reviewed the data of 3332 patients (2722 elderly [65 to 79 years], and 610 octogenarians [\geq 80 years]). The cumulative hazard of MACCE was significantly higher in the octogenarian group compared with the younger group (*P*<0.001). MACCE in octogenarians presenting with ST-elevation myocardial infarction (STEMI) was significantly higher than those with non-ST-elevation myocardial infarction/Unstable angina (NSTEMI/UA) (*P*<0.001); however, the cumulative hazard of mortality was not significantly different between the two groups (*P*=0.270). Successful PCI, left main stenosis and estimated glomerular filtration rate (eGFR) were independent predictors of MACCE in octogenarians with ACS.

Conclusion: Octogenarians undergoing PCI had a higher rate of MACCE and mortality compared with a younger population. In octogenarians, MACCE in those with STEMI was significantly higher than those with NSTEMI/UA and the mortality trend was similar; however, the 1-year trend was in favor of the STEMI subgroup.

Keywords: Elderly, Major adverse cardiac events, Octogenarian, Percutaneous coronary intervention

Cite this article as: Fallahzadeh A, Sheikhy A, Aein A, Salarifar M, Pourhosseini H, Aghajani H, et al. Outcome of percutaneous coronary intervention in old patients presenting with acute coronary syndrome. Arch Iran Med. 2022;25(8):523-532. doi: 10.34172/aim.2022.84

Received: February 14, 2021, Accepted: September 1, 2021, ePublished: August 1, 2022

Introduction

With the increasing life expectancy and falling mortality rate, the octogenarian population in Iran has been increasing sharply during the past decades. By the year 2050, it is expected to have almost 3.5 million persons aged 80 years and above, which account for 3.8% of the total population.¹

The prevalence of coronary artery disease is increasing in the elderly and cardiovascular disease has been established in about 80% of octogenarian population.^{2,3} With advancing population age, elderly patients with acute coronary syndrome (ACS) (ST segment elevated myocardial infarction [STEMI], non-ST segment elevated myocardial infarction [NSTEMI] and unstable angina [UA]) will represent a great proportion of patients undergoing percutaneous coronary intervention (PCI).⁴ Although PCI is associated with improved survival in octogenarians compared with medical therapy alone, the elderly undergoing PCI are at higher risk of adverse outcomes and mortality compared to young patients.⁵ This emphasizes the importance of identifying prognostic factors associated with adverse outcomes after PCI in octogenarians.

Although studies have shown that mortality is higher in older patients undergoing PCI compared to young individuals,^{6.7} the differences in PCI outcomes between the elderly (65–79 years) and octogenarians (\geq 80 years) have not been well described. Moreover, comparing outcomes among octogenarians presenting with STEMI or NSTEMI/UA is another issue that has not been clearly addressed in previous studies. Finding the perioperative risk factors which affect the outcome is necessary since they could influence clinical decision and patient selection.⁸ Several well-designed clinical trials have been conducted previously to establish the outcome of PCI in elderly patients,^{9,10} but clinical trials are not capable to determine predictors.

In this registry-based cohort study, we aimed to evaluate

the short-term outcome of PCI in patients aged 65-79 years and \geq 80 years. Moreover, we identified the independent predictors of major adverse cerebrocardiovascular events (MACCEs) in octogenarians presenting with STEMI or NSTEMI/UA.

Materials and Methods Study Design

In accordance with the statement checklist outlined in Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), we conducted a registrybased, single-center cohort study in Tehran Heart Center (THC).¹¹ Patient characteristics and procedural details were recorded prospectively at the time of procedure and afterwards during each follow-up visit. The THC ethical board approved the study (IR-THC-13799). This study did not meet the criteria for informed consent; consequently, an "informed consent waiver" was obtained from the THC ethical board.

Study Population

The entire cohort included 8126 patients with ACS who underwent coronary angiogram and PCI between April 2015 and December 2019. Our inclusion criteria were: 1) age \geq 65 years; 2) adequate pre-operative characteristics and 3) completion of follow-up visits. The main exclusion criterion was incomplete clinical and angiographic data. Eventually, 3332 patients remained in the study. The clinical follow-up data were collected by regular clinic visits (64.3% of patients) or direct telephone interviews (33.0% of patients). The patients' follow-up protocol was at 4th, 6th, and 12th month after PCI and annually thereafter. Patients were stratified into two groups; 65 to 79 years old (elderly), which included 2722 (81.69%) patients, and \geq 80 years old (octogenarian), which included 610 (18.31%)

patients (Figure 1). The octogenarian group included all patients aged \geq 80 years¹² at the time of PCI, and patients did not switch groups if they passed the age of 80 years during the follow-up period.

Definition of Variables

Data of the study population were retrieved from the angiography/PCI databank of our center.

ACS refers to a spectrum of clinical presentations ranging from those for STEMI to presentations found in NSTEMI or in UA. The definition of hypertension was based on the presence of at least one of the following conditions; minimum systolic blood pressure of 140 mm Hg, or minimum diastolic blood pressure of 90 mm Hg, or history of taking antihypertensive drugs.¹³ The definition of dyslipidemia was based on the presence of a minimum total cholesterol of 240 mg/dL, a minimum triglyceride of 200 mg/dL, a high-density lipoprotein cholesterol < 40 mg/dL in men and < 50 mg/dL in women, a minimum low-density lipoprotein cholesterol level of 160 mg/dL, or history of taking lipid-lowering drugs.14,15 We determined cigarette smoking and opium usage based on patient's self-reported status. A current smoker was a person who currently smokes and has ever smoked more than 100 cigarettes.¹⁶ Based on the American Diabetes Association, diabetes mellitus was defined as the presence of a definite history of diabetes with records of treatment or fasting blood sugar \geq 126 mg/dL or 2-hour postprandial glucose≥200 mg/dL.¹⁷ Positive family history was defined as a first-degree relative younger than 55 years (men) or 65 years (women) with coronary artery disease. Infarct-related artery was the artery that underwent stent implantation during the PCI procedure. The thrombolysis in myocardial infarction (TIMI) flow grade is a method for the assessment of coronary artery flow in ACS. It



Figure 1. Flow Diagram of the Study Population

is classified as grade 0 (no flow), grade 1 (penetration without perfusion), grade 2 (partial perfusion) or grade 3 (complete perfusion). Left main (LM) stenosis referred to those with stenosis of the left main coronary artery < 50% on angiogram.

Procedural Technique

The standard techniques with the femoral approach were applied for performing PCI procedures. According to our procedure routine, before the procedure, all patients received a 300–600 mg loading dose of clopidogrel plus 325 mg aspirin. During the procedure, patients received 70–100 IU/kg intravenous unfractionated heparin. Clopidogrel (75 mg/d) and aspirin (81 mg/d) were maintained for at least 1-year after the procedure.

Study Endpoints

All-cause mortality and MACCE occurrence (including all-cause mortality, non-fatal ACS, non-fatal stroke or transient ischemic attack, and repeat coronary revascularization via PCI or Coronary artery bypass graft surgery) were considered as primary endpoints.

Statistical Analysis

Normally and skewed distributed continuous variables were presented as mean with standard deviation (SD) and median with 25th and 75th percentiles (interquartile range [IQR] boundaries), respectively. Histogram charts as well as central tendency and dispersion measures were used to assess the normality of variables. Student's *t* test and Mann-Whitney U-test were used to compare normally and skewed distributed variables, respectively. Discrete variables were presented as frequency and percentages, and compared between groups using the Chi-square test.

A univariate Cox regression model was used to assess the univariate effects of covariates on mortality and MACCE, and reported as hazards ratio (HR) with 95% confidence intervals (CIs). We entered covariates with *P* values < 0.1 on the univariate Cox regression into the multivariate model. The decision of what to include in the multivariable models was based on an *a priori* hypothesis and if adding/ removing a variable made a big change (e.g., >10%) in the estimates. Moreover, for each final variable, we tested the proportional hazard (PH) assumption through graphical assessment based on the scaled Schoenfeld residuals. The assumption was met for each variable conclusively (Supplementary file 1, Figure S1).

We used the Stata Statistical Software, release 14 (College Station, TX: StataCorp LP) and R version 4.0.3 for all statistical analyses.¹⁸ The following packages in R were used: "survival" (package for survival analysis in R),¹⁹ "survminer" (drawing survival curves),²⁰ and "ggplot2".²¹

Results

Patient Characteristics

The baseline and procedural characteristics of the study population are shown in Table 1. In the STEMI

subgroup, the proportion of female patients was 36.7% in octogenarians, significantly higher than the elderly (P=0.001), and the median age was 83 [81-89] and 70 [67-75] years, respectively. Procedural characteristics were not different between the two groups except for stent length and diameter.

In the NSTEMI subgroup, the median age was 83 [81-86] years in octogenarian and 70 [67-75] years in elderly patients. Multivessel disease was significantly higher in the octogenarian group compared with younger individuals (70.7% vs. 66.1%, P = 0.027).

Outcomes

The occurrence of study endpoints in these two groups is shown in Table 2.

According to Kaplan–Meier analysis, the cumulative hazard of MACCE was significantly higher in the octogenarian group in comparison with younger patients (median follow-up 12.06 months [IQR: 7.36-13.23 months], P < 0.001) (Figure 2A). The Kaplan-Meier survival curve demonstrated that survival was significantly lower in octogenarians compared to the elderly (P < 0.001) (Figure 2B).

Octogenarian Subgroup Analysis

The baseline and procedural characteristics of the octogenarian subgroup based on the occurrence of MACCE are shown in Table 3.

Kaplan–Meier analysis showed that the cumulative hazard of MACCE in octogenarians presenting with STEMI was significantly higher than those with NSTEMI/ UA (P<0.001); however, the cumulative hazard of mortality was not significantly different between the two groups (P=0.270). Although the mortality trend looked similar in the first 6 months, the 1-year trend was in favor of the STEMI subgroup (Figures 3A and 3B).

The independent predictors of MACCE in octogenarians presenting with STEMI or NSTEMI/UA are shown in Figure 4 and Tables S1 and S2. In octogenarians presenting with STEMI; postprocedural TIMI flow 3 (HR 0.29 [95% CI: 0.16–0.53]), LM stenosis (HR 1.84 [95% CI: 0.92– 3.66]) and estimated glomerular filtration rate (eGFR) (HR 0.98 [95% CI:0.96-0.99]) were the predictors, and in patients presenting with NSTEMI/UA; postprocedural TIMI flow 3 (HR 0.22 [95% CI: 0.10–0.49]), LM stenosis (HR 2.50 [95% CI: 1.17–5.34]), eGFR (HR 0.97 [95% CI: 0.95–0.99]), and dyslipidemia (HR 0.37 [95% CI: 0.19– 0.72]) were the independent predictors of MACCE.

Discussion

In the present study, we compared MACCE and mortality between the elderly and octogenarian subgroups and also identified the prognostic predictors of MACCE in the octogenarian population, one year after undergoing PCI due to ACS. We showed that MACCE and mortality were significantly higher in octogenarians compared with younger adults. Successfully performed PCI (defined as

Table 1. Baseline and Procedural Characteristics by Age

	STEMI			NSTEMI		
	65-80 Years	≥80 Years	P Value	65-80 Years	≥80 Years	P Value
Total number	1163 (78.59%)	320 (21.41%)	< 0.001	1559 (84.13%)	290 (15.87%)	< 0.001
Female	348 (30.0%)	116 (36.7%)	0.001	549 (35.2%)	93 (31.6%)	0.088
Age (median, IQR) (y)	70 [67–75]	83 [81-89]	< 0.001	70 [67–75]	83 [81–86]	< 0.001
BMI (mean, SD) (kg/m ²)	27.58 (4.41)	26.35 (4.76)	< 0.001	27.96 (4.66)	26.64 (4.86)	< 0.001
eGFR (median, IQR) (mL/min)	65.91 [51.13-83.48]	42.31 [32.11–57.84]	< 0.001	64.64 [51.85–79.82]	45.26 [34.41–58.27]	< 0.001
LVEF (mean, SD) (%)	41.17 (8.78)	38.77(9.08)	< 0.001	46.83 (8.90)	43.85 (10.34)	< 0.001
Family history	128 (11.0%)	22 (7.0%)	0.001	204 (13.1%)	30 (10.2%)	0.043
Dyslipidemia	608 (52.4%)	127 (40.2%)	< 0.001	950 (60.9%)	140 (47.6%)	< 0.001
Previous MI	67 (5.6%)	21 (6.6%)	0.356	578 (38.1%)	137 (47.2%)	< 0.001
Hypertension	678 (58.4%)	198 (62.7%)	0.049	971 (62.3%)	195 (66.3%)	0.062
Diabetes mellitus	559 (48.2%)	132 (41.8%)	0.004	616 (39.5%)	98 (33.3%)	0.004
Smoking	414 (35.7%)	72 (22.8%)	< 0.001	510 (32.7%)	63 (21.4%)	< 0.001
Opium consumption	153 (13.2%)	20 (6.3%)	< 0.001	171 (11.0%)	21 (7.1%)	0.002
Cerebrovascular disease	68 (5.9%)	19 (6.0%)	0.925	53 (3.4%)	19 (6.5%)	0.001
COPD	31 (2.7%)	12 (3.8%)	0.165	54 (3.5%)	8 (2.7%)	0.302
Infarct-related artery						
Left main artery	6 (0.5%)	0		17 (1.1%)	6 (2.1%)	
Left anterior descending artery	556 (46.2%)	170 (53.1%)		670 (44.1%)	154 (53.1%)	
Left circumflex artery	218 (18.1%)	49 (15.3%)	0.254	322 (21.2%)	55 (19%)	0.011
Right coronary artery	361 (30.0%)	83 (25.9%)		366 (24.1%)	48 (16.6%)	
Saphenous vein graft	52 (4.3%)	13 (4.1%)		129 (8.5%)	25 (8.6%)	
Multivessel disease	823 (70.9%)	227 (71.8%)	0.656	1031 (66.1%)	208 (70.7%)	0.027
Left main stenosis	105 (9%)	40 (12.6%)		118 (7.5%)	30 (10.2%)	
Preprocedural TIMI flow						
0	706 (60.9%)	187 (59.2%)	0.333	161 (10.3%)	24 (8.2%)	
1	66 (5.7%)	16 (5.1%)		40 (2.6%)	6 (2.0%)	0.422
2	200 (17.2%)	68 (21.5%)		168 (10.8%)	39 (13.3%)	0.722
3	188 (16.2%)	45(14.2%)		1190 (76.3%)	225 (76.5%)	
Postprocedural TIMI flow						
0	41 (3.5%)	14 (4.4%)	0.241	34 (2.2%)	8 (2.7%)	
1	7 (0.6%)	5 (1.6%)		6 (0.4%)	1 (0.3%)	0.599
2	66 (5.7%)	14 (4.4%)		22 (1.4%)	7 (2.4%)	
3	1046 (90.2%)	283 (89.6%)		1497 (96.0%)	278 (94.6%)	
ACC/AHA type						
A	2 (0.2%)	0		2 (0.1%)	0	0.558
B1	82 (7.1%)	23 (7.3%)	0.252	383 (24.6%)	77 (26.1%)	
B2	166 (14.3%)	55 (17.4%)	0.200	219 (14.0%)	40 (13.6%)	
С	910 (78.4%)	238 (75.3%)		955 (61.3%)	177 (60.2%)	
Stent diameter (median, IQR) (mm)	2.75 [2.5-3]	3 [2.75, 3]	< 0.001	3 [2.75, 3.25]	3 [2.75, 3.5]	0.409
Stent length (median, IQR) (mm)	24 [19, 33]	28 [20, 38]	0.024	24 [18, 33]	23 [18, 32]	0.731
Stent thrombosis	21 (1.8%)	5 (1.6%)	0.119	5 (0.3%)	0	< 0.001

BMI, Body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; TIMI, thrombolysis in myocardial infarction.



 Table 2. Patients' Outcomes by Age

post-procedural TIMI flow 3) and higher level of eGFR were associated with lower risk of MACCE, and LM stenosis was associated with higher risk of MACCE in both STEMI and NSTEMI/UA groups.

The pathophysiological mechanisms and clinical symptoms of ACS in octogenarians differ from those in younger patients. Octogenarians are known to have more complex lesions as well as multivessel disease.6 PCI is an accepted treatment choice for revascularization in the elderly.²² However, the higher presence of cardiac and non-cardiac diseases, worse endothelial function and increased calcification will lead to higher rates of adverse events after PCI in the elderly compared to young patients.²³ As the elderly population is increasing globally due to advanced health care, evaluating the survival and identifying the predictors of MACCE in octogenarians after PCI becomes a more important issue.²⁴ The higher risk of death in octogenarians is partly due to the presence of comorbid conditions such as hypertension, diabetes, ventricular dysfunction, heart failure, peripheral vascular disease and renal failure as well as procedural complications such as bleeding events, shock, and hemodynamic instability.7,25,26 Another explanation for the poor outcome in octogenarians is delayed reperfusion in the elderly due to late presentation and atypical symptoms.²⁷ Yan et al evaluated 4,360 patients who underwent PCI and showed that octogenarians had significantly increased risk of mortality and major adverse cardiac events (MACE) at 30-days and 1-year after PCI compared to those aged < 80 years.⁶ Batchelor et al evaluated in-hospital outcomes and showed that

octogenarians had increased risk of mortality and the composite outcome of death/myocardial infarction (MI)/ cerebrovascular accident compared to those < 80 years.⁷ Fach et al assessed patients presenting with STEMI and showed that mortality and MACE rates significantly increased with age, as we reported in the present study.²⁸ Feldman et al evaluated the effect of age on short-term prognosis after PCI in three age groups (<60, 60–80, and > 80 years) and showed that in both emergency and elective PCI groups, MACE increased with age.²⁹

In the present study, MACCE was significantly higher in octogenarians with STEMI compared to NSTEMI/ UA. Mortality during the first 6 months of follow-up was higher in octogenarians presenting with STEMI compared to NSTEMI/UA individuals; however, on longer followup, NSTEMI/UA patients tend to have higher mortality. This higher mortality in STEMI patients can be explained by the higher incidence of mechanical complications as well as cardiogenic shock in the acute stage of STEMI that are associated with high risk of mortality.^{30,31} In line with our results, the higher rate of MACCE in patients with STEMI after PCI compared to those with NSTEMI has been reported in previous studies.32 Bouisset et al compared short- and long-term mortality rates in STEMI and NSTEMI patients and showed that the short-term (28day) mortality was significantly worse in STEMI patients; however, over longer follow-up periods NSTEMI patients had similar risk of death compared to STEMI patients.³³ Another study conducted by Hirsch et al evaluated early and late outcomes in patients undergoing PCI and showed that patients with STEMI had a great risk of mortality

Table 3. Patients' Characteristics in the Octogenarian Group (\geq 80 years) by MACCE Occurrence

	STEMI			NSTEMI			
_	MACCE+	MACCE -	P Value	MACCE+	MACCE -	P Value	
Total number	77	243		47	243		
Female	28 (36.4%)	90 (37.0%)	0.915	13 (27.7%)	78 (32.1%)	0.548	
Age (mean, SD) (y)	85.13 (4.4)	84.26 (3.8)	0.099	83.66 (3.6)	83.57 (3.1)	0.860	
$BMI \;(mean,\;SD)\;(kg\!/m^2)$	26.88 (5.2)	26.17 (4.6)	0.279	26.37 (4.3)	26.67 (4.9)	0.700	
eGFR (mean, SD) (mL/min)	46.31 (18.0)	51.48 (17.6)	0.034	45.87 (18.1)	54.18 (19.3)	0.007	
LVEF (mean, SD) (%)	36.43 (10.5)	38.15 (11.05)	0.262	34.45 (16.4)	41.81 (14.1)	0.002	
Family history	6 (7.8%)	17 (7.0%)	0.814	5 (10.6%)	24 (9.9%)	0.795	
Dyslipidemia	30 (39.0%)	98 (40.3%)	0.831	15 (31.9%)	124 (51%)	0.016	
Previous MI	3 (3.9%)	18 (7.4%)	0.428	21 (44.7%)	116 (47.4%)	0.701	
Hypertension	48 (62.3%)	153 (63%)	0.921	32 (68.1%)	160 (65.8%)	0.766	
Diabetes mellitus	40 (51.9%)	94 (38.7%)	0.043	18 (38.3%)	78 (32.1%)	0.408	
Smoking	15 (19.5%)	57 (23.5%)	0.467	11 (23.4%)	52 (21.4%)	0.760	
Opium consumption	4 (5.2%)	16 (6.6%)	0.792	1 (2.1%)	20 (8.2%)	0.217	
Cerebrovascular disease	5 (6.5%)	14 (5.8%)	0.781	2 (4.3%)	17 (7%)	0.748	
COPD	1 (1.3%)	11 (4.5%)	0.306	2 (4.3%)	6 (2.5%)	0.620	
Infarct-related artery							
Left main artery	0	0		3 (6.4%)	3 (1.2%)		
Left anterior descending artery	44 (57.1%)	126 (51.9%)		19 (40.4%)	135 (55.6%)		
Left circumflex artery	17 (22.1%)	32 (13.2%)	0.087	10 (21.3%)	45 (18.5%)	0.047	
Right coronary artery	13 (16.9%)	70 (28.8%)		7 (14.9%)	41 (16.9%)		
Saphenous vein graft	3 (3.9%)	10 (4.1%)		7 (14.9%)	18 (7.4%)		
Multivessel disease	56 (72.7%)	174 (71.6%)	0.849	39 (83%)	166 (68.3%)	0.043	
Left main stenosis	14 (18.2%)	26 (10.7%)	0084	11 (23.4%)	19 (7.8%)	0.001	
Preprocedural TIMI flow							
0	50 (64.9%)	137 (56.4%)		8 (17%)	16 (6.6%)	0.054	
1	5 (6.5%)	11 (4.5%)	0.356	0	6 (2.5%)		
2	14 (18.2%)	54 (22.2%)	0.550	8 (20.5%)	31 (12.8%)		
3	8 (10.4%)	41 (16.9%)		31 (66%)	190 (78.2%)		
Postprocedural TIMI flow							
0	7 (9.1%)	8 (3.3%)		5 (10.6%)	2 (0.8%)	< 0.001	
1	2 (2.6%)	3 (1.2%)	< 0.001	1 (2.1%)	0		
2	9 (11.7%)	5 (2.1%)	<0.001	3 (6.4%)	4 (1.6%)		
3	59 (76.6%)	227 (93.4%)		38 (80.9%)	237 (97.5%)		
ACC/AHA type							
A	0	1 (0.4%)		0	0	0.674	
B1	5 (6.5%)	18 (7.4%)	0.891	11 (23.4%)	65 (26.7%)		
B2	15 (19.5%)	41 (16.9%)	0.001	5 (10.6%)	34 (14.0%)		
С	57 (74%)	183 (75.3%)		31 (66%)	144 (59.3%)		
Stent diameter (mean, SD) (mm)	2.77 (0.34)	2.87 (0.43)	0.106	3.05 (0.4)	2.96 (0.4)	0.302	
Stent length (mean, SD) (mm)	27.07 (10.4)	27.05 (9.4)	0.990	25.13 (8.07)	25.06 (9.3)	0.971	
Stent thrombosis	2 (2.6%)	3 (1.2%)	0.597	0	0		

BMI, Body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; TIMI, thrombolysis in myocardial infarction.



Figure 3. Kaplan-Meier Curves Showing Cumulative Hazard of (A) MACCE and (B) Death in Patients > 80 Years in the Two Groups (STEMI and NSTEMI/UA)





NSTEMI



Figure 4. Final Predictors of MACCE in Patients>80 Years in The Two Groups (STEMI and NSTEMI/UA)

during the first 6 months but survival was similar to those with NSTEMI/UA thereafter – up to 6 years.³⁴

Although invasive approaches such as PCI are associated with increased risk of adverse outcomes in the elderly, medical management in octogenarians was associated with 50% chance of later hospitalization and revascularization.³⁵ Thus, it is reasonable to select patients and identify factors associated with PCI outcomes in octogenarians in order to achieve the optimal prognosis. Our findings emphasize the essential role of successfully performed PCI (defined as post-procedural TIMI flow 3) in old patients presenting with both STEMI or NSTEMI/UA. The prognostic impact of successful revascularization therapy in young patients has been proved in several randomized trials; but only few studies emphasized the importance of successful PCI in elderly patients with STEMI or NSTEMI/UA. Octogenarians have more complex lesions and higher prevalence of left main stenosis compared to the younger population and thus, undergo more complex PCI procedures.¹² As we identified in our study, left main stenosis was associated with higher risk of MACCE in both STEMI and NSTEMI/ UA patients.

Similar to our findings, Miranda Malpica et al evaluated 73 patients (\geq 80 years) and showed that the predictors of 1-year MACE and mortality were pre- and postoperative TIMI flow < 3 and diabetes mellitus.³⁶ However, in our study, only post-operative TIMI flow <3 flow was associated with higher risk of MACCE. Bauer et al evaluated 47407 patients undergoing PCI and identified the independent predictors of in-hospital mortality in those \geq 75 years.²⁷ Similar to our results, TIMI flow after PCI was associated with death after PCI. Another study conducted by Bromage et al analyzed 10249 patients with STEMI treated with primary PCI and showed that 5-years mortality was significantly higher in patients \geq 80 years.37 Moreover, the independent predictors of allcause mortality in octogenarians were renal failure, ejection fraction < 30%, and TIMI flow 3. According to results from the Bremen STEMI Registry, successful PCI (defined as TIMI flow 2 or 3 after PCI) was associated with lower in-hospital and 1-year mortality in elderly patients presenting with STEMI; also, similar to our findings, diabetes mellitus was not a predictor of in-hospital mortality after PCI.28 Caretta et al evaluated 139 patients (>80 years) and showed that in univariate analysis, older age, TIMI flow < 3, diabetes, left main stenosis and left ventricular ejection fraction (LVEF) < 40% were associated with higher 1-year mortality; however, only TIMI flow<3 and LVEF<40% were the independent predictors of 1-year mortality.³⁸ Batchelor et al evaluated 7472 octogenarians who underwent PCI and showed that diabetes mellitus, LVEF < 35%, renal failure, and cardiac shock were independent predictors of mortality.7 Moreover, in our study, dyslipidemia was associated with lower risk of MACCE in NSTEMI patients; one possible explanation for the protective effect of dyslipidemia

might be that the use of lipid-lowering therapy such as statins before PCI is more likely in patients with dyslipidemia. The risk of all-cause mortality and MACE after revascularization has been shown to be lower in those receiving statin.^{39,40} Another explanation might be that patients with known dyslipidemia are considered high-risk and thus, they receive higher doses of statins and also, they are more expected to have regular exercise and healthy diets, to be aware of the risk of cardiovascular diseases, and to manage cardiovascular risk factors such as hypertension. However, this was beyond the scope of our study and further studies are needed to explain this possible protective effect.

Strength and Limitation

The present study has some possible limitations. Our results were based on short-term follow-up (median 12 months), and for more accurate results, further studies with longer follow-up periods are warranted. This a single-center study which should be taken into consideration when assessing the generalizability of our findings. However, THC is a referral educational university and admits patients from all over the country.

The major strengths of this study are the high power of the study due to its large sample size and consequently, high prevalence of events. Moreover, we extracted our data from the THC registry databank, which records the individuals' data prospectively.

Conclusion

In this registry-based study, we found that MACCE and mortality were higher in octogenarians who underwent PCI, compared to younger adults. Moreover, in our octogenarian patient cohort, the risk of MACCE was higher in those presenting with STEMI compared to NSTEMI/UA and the mortality trend was similar in the first 6 months; however, the 1-year trend was in favor of the STEMI subgroup. Our data also provided insights into the independent predictors of MACCE in octogenarians after 1-year follow-up.

Authors' Contribution

AF contributed to method development, interpretation of results and writing the manuscript. Ash contributed to method development, data collection and result interpretation. KH was the mentor of the team, reviewed and edited the manuscript. AA contributed in data collection and criticized the method. MS, HP, HA, MA were the members of the expert panel. SS reviewed, criticized and edited the manuscript. All authors reviewed the manuscript and they agree with the final version.

Conflict of Interest Disclosures

The authors declare that they have no conflict of interest.

Ethical Statement

The THC ethical board approved the study (IR-THC-13799).

Funding

None.

Supplementary Materials

Supplementary file 1 contains Tables S1-S2 and Figure S1.

References

- 1. Mehri N, Messkoub M, Kunkel S. Trends, Determinants and the Implications of Population Aging in Iran. Ageing Int. 2020;45(4):327-343. doi:10.1007/s12126-020-09364-z.
- Ozen A, Unal EU, Songur M, Kocabeyoglu SS, Hanedan O, Yilmaz M, et al. Coronary artery bypass grafting in the octogenarians: should we intervene, or leave them be? J Geriatr Cardiol. 2015;12(2):147-52. doi: 10.11909/j. issn.1671-5411.2015.02.005.
- Natarajan A, Samadian S, Clark S. Coronary artery bypass surgery in elderly people. Postgrad Med J. 2007;83(977):154-8. doi: 10.1136/pgmj.2006.049742.
- Helft G, Georges JL, Mouranche X, Loyeau A, Spaulding C, Caussin C, et al. Outcomes of primary percutaneous coronary interventions in nonagenarians with acute myocardial infarction. Int J Cardiol. 2015;192:24-9. doi: 10.1016/j. ijcard.2015.04.227.
- Antonsen L, Jensen LO, Terkelsen CJ, Tilsted HH, Junker A, Maeng M, et al. Outcomes after primary percutaneous coronary intervention in octogenarians and nonagenarians with ST-segment elevation myocardial infarction: from the Western Denmark heart registry. Catheter Cardiovasc Interv. 2013;81(6):912-9. doi: 10.1002/ccd.24591.
- Yan BP, Gurvitch R, Duffy SJ, Clark DJ, Sebastian M, New G, et al. An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry. Catheter Cardiovasc Interv. 2007;70(7):928-36. doi: 10.1002/ccd.21303.
- Batchelor WB, Anstrom KJ, Muhlbaier LH, Grosswald R, Weintraub WS, O'Neill WW, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol. 2000;36(3):723-30. doi: 10.1016/s0735-1097(00)00777-4.
- Ipek G, Kurmus O, Koseoglu C, Onuk T, Gungor B, Kirbas O, et al. Predictors of in-hospital mortality in octogenarian patients who underwent primary percutaneous coronary intervention after ST segment elevated myocardial infarction. Geriatr Gerontol Int. 2017;17(4):584-590. doi: 10.1111/ ggi.12759.
- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20. doi: 10.1016/S0140-6736(03)12113-7.
- Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570-89. doi: 10.1161/ CIRCULATIONAHA.107.182616.
- 11. Poorhosseini H, Abbasi SH. The Tehran Heart Center. Eur Heart J. 2018;39(29):2695-6. doi: 10.1093/eurheartj/ehy369.
- Shanmugam VB, Harper R, Meredith I, Malaiapan Y, Psaltis PJ. An overview of PCI in the very elderly. J Geriatr Cardiol. 2015;12(2):174-84. doi: 10.11909/j.issn.1671-5411.2015.02.012.
- Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. doi: 10.1111/jch.12237.

- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
- Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol. 2006;21(4):400-4. doi: 10.1097/01.hco.0000231412.15049.fb.
- Center for Disease Control and Prevention. Smoking and Tobacco Use. Available from: https://www.cdc.gov/tobacco/ data_statistics/fact_sheets/fast_facts/index.htm.
- 17. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009;32(Suppl 1):S62-S67. doi:10.2337/dc09-S062.
- R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria; 2020.
- 19. Terry Therneau. A Package for Survival Analysis in R_. R package version 3.2-10. 2021.
- 20. Kassambara A. survminer: Drawing Survival Curves using 'ggplot2'. R package version 0.4.9. 2021.
- 21. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2016.
- 22. Shanmugasundaram M. Percutaneous coronary intervention in elderly patients: is it beneficial? Tex Heart Inst J. 2011;38(4):398-403.
- 23. Bauer T, Zeymer U. Impact of age on outcomes of percutaneous coronary intervention in acute coronary syndromes patients. Interv Cardiol. 2010;2:319-325.
- 24. Shafiee A, van Bodegom D. The necessity for research on the elderly in iran. J Tehran Heart Cent. 2012;7(1):40.
- Assali AR, Moustapha A, Sdringola S, Salloum J, Awadalla H, Saikia S, et al. The dilemma of success: percutaneous coronary interventions in patients>or=75 years of age-successful but associated with higher vascular complications and cardiac mortality. Catheter Cardiovasc Interv. 2003;59(2):195-9. doi: 10.1002/ccd.10532.
- Bauer T, Möllmann H, Weidinger F, Zeymer U, Seabra-Gomes R, Eberli F, et al. Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. Int J Cardiol. 2011;151(2):164-9. doi: 10.1016/j.ijcard.2010.05.006.
- Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. Am Heart J. 2006;151(6):1231-8. doi: 10.1016/j.ahj.2005.07.016.
- Fach A, Bünger S, Zabrocki R, Schmucker J, Conradi P, Garstka D, et al. Comparison of Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention Analyzed by Age Groups (<75, 75 to 85, and>85 Years); (Results from the Bremen STEMI Registry). Am J Cardiol. 2015;116(12):1802-9. doi: 10.1016/j.amjcard.2015.09.022.
- Feldman DN, Gade CL, Slotwiner AJ, Parikh M, Bergman G, Wong SC, et al. Comparison of outcomes of percutaneous coronary interventions in patients of three age groups (<60, 60 to 80, and>80 years) (from the New York State Angioplasty Registry). Am J Cardiol. 2006;98(10):1334-9. doi: 10.1016/j. amjcard.2006.06.026.
- Aissaoui N, Puymirat E, Delmas C, Ortuno S, Durand E, Bataille V, et al. Trends in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail. 2020;22(4):664-672. doi: 10.1002/ejhf.1750.
- Elbadawi A, Elgendy IY, Mahmoud K, Barakat AF, Mentias A, Mohamed AH, et al. Temporal Trends and Outcomes of Mechanical Complications in Patients With Acute Myocardial

Infarction. JACC Cardiovasc Interv. 2019;12(18):1825-1836. doi: 10.1016/j.jcin.2019.04.039.

- 32. Ghadri JR, Jaguszewski M, Sacron A, Srikantharupan S, Pfister P, Siddique A, et al. Current outcome of acute coronary syndromes: data from the Zurich-Acute Coronary Syndrome (Z-ACS) Registry. Cardiovascular Medicine. 2013;13(4):115-122. doi: 10.5167/uzh-91028
- Bouisset F, Ruidavets JB, Dallongeville J, Moitry M, Montaye M, Biasch K, et al. Comparison of Short- and Long-Term Prognosis between ST-Elevation and Non-ST-Elevation Myocardial Infarction. J Clin Med. 2021;10(2):180. doi: 10.3390/jcm10020180.
- 34. Hirsch A, Verouden NJ, Koch KT, Baan J Jr, Henriques JP, Piek JJ, et al. Comparison of long-term mortality after percutaneous coronary intervention in patients treated for acute ST-elevation myocardial infarction versus those with unstable and stable angina pectoris. Am J Cardiol. 2009;104(3):333-7. doi: 10.1016/j.amjcard.2009.03.052.
- TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358(9286):951-7. doi: 10.1016/S0140-6736(01)06100-1.
- 36. Miranda Malpica E, Peña Duque MA, Castellanos J, Exaire E, Arrieta O, Salazar Dávila E, et al. Predictors of mortality and adverse outcome in elderly high-risk patients undergoing percutaneous coronary intervention. Arch Cardiol Mex.

2007;77(3):194-9.

- 37. Bromage DI, Jones DA, Rathod KS, Grout C, Iqbal MB, Lim P, et al. Outcome of 1051 Octogenarian Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Observational Cohort From the London Heart Attack Group. J Am Heart Assoc. 2016;5(6):e003027. doi: 10.1161/JAHA.115.003027.
- Caretta G, Passamonti E, Pedroni PN, Fadin BM, Galeazzi GL, Pirelli S. Outcomes and predictors of mortality among octogenarians and older with ST-segment elevation myocardial infarction treated with primary coronary angioplasty. Clin Cardiol. 2014;37(9):523-9. doi: 10.1002/clc.22313.
- 39. Kim YH, Her AY, Jeong MH, Kim BK, Shin DH, Kim JS, et al. Two-year outcomes of statin therapy in patients with acute myocardial infarction with or without dyslipidemia after percutaneous coronary intervention in the era of newgeneration drug-eluting stents within Korean population: Data from the Korea Acute Myocardial Infarction Registry. Catheter Cardiovasc Interv. 2019;93(7):1264-1275. doi: 10.1002/ ccd.27985.
- Ng AK, Ng PY, Ip A, Siu CW. High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong. Front Cardiovasc Med. 2021;8:760926. doi: 10.3389/fcvm.2021.760926.

2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons. org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.